Rcomparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure

Oncologist

Volumn 20, Issue 5, 2015, Pages 516-522

  Green, Angela K ^a   Corty, Robert W ^b   Wood, William A ^a   Meeneghan, Mathew ^a   Reeder Hayes, Katherine E ^a   Basch, Ethan ^a   Milowsky, Matthew I ^a   Dusetzina, Stacie B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Comparative effectiveness research; Mitoxantrone; Postdocetaxel; Project data sphere; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DATA PROCESSING; DRUG EFFICACY; DYSPNEA; ELECTROCARDIOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84929070519     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0432     Document Type: Article

References (12)

1. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone inmenwith hormone-refractory prostate cancer: Results of the cancerand leukemia groupB9182study. J Clin Oncol 1999;17:2506–2513.
2. Osoba D, Tannock IF, Ernst DS et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654–1663.
3. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14: 1756–1764.
4. Berry W, Dakhil S, Modiano M et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2439–2443.
5. Berthold DR, Pond GR, Roessner M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14:2763–2767.
6. Bahl A, Oudard S, Tombal B et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24:2402–2408.
7. Carpenter WR, Meyer AM, Abernethy AP et al. A framework for understanding cancer comparative effectiveness research data needs. J Clin Epidemiol 2012;65:1150–1158.
8. Sunitinib plus prednisone in patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy (SUN 1120). Available at http://clinicaltrials.gov/show/NCT00676650. Accessed April 8, 2015.
9. Michaelson MD, Oudard S, Ou Y-C et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castrationresistant prostate cancer. J Clin Oncol 2014;32: 76–82.
10. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147–1154.
11. Halabi S, Lin CY, Small EJ et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013;105:1729–1737.
12. Ho DE, Imai K, King G et al. MatchIt: Nonparametric preprocessing for parametric causal inference. J Stat Softw 2011;42:1–28.